Ceftriaxone sodium salt
Based on 22 publication(s) in Google Scholar
Ceftriaxone sodium salt (Ro 13-9904) is a broad spectrum β-lactam third-generation cephalosporin antibiotic, which has good antibacterial activity against a variety of gram-negative and positive bacteria. Ceftriaxone sodium salt is a covalent inhibitor of GSK3β with IC50 value of 0.78 μM. Ceftriaxone sodium salt is an inhibitor of Aurora B. Ceftriaxone sodium salt has anti-inflammatory, antitumor and antioxidant activities. Ceftriaxone sodium salt can be used in the study of bacterial infections and meningitis.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 99.90%
- CAS. Nr.: 74578-69-1
- Formel: C18H16N8Na2O7S3
- Molecular Weight:598.54
-
Speicherung:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
HY-B0467B
Amoxicillin trihydrateAntibiotic -
HY-B1117
Cefoxitin sodiumAntibiotic -
HY-13678
MeropenemAntimicrobial Agent -
HY-A0256
Clavulanic acidβ-lactamase Inhibitor -
HY-B0318
MetronidazoleAntibiotic -
HY-10394
LinezolidAntibiotic -
HY-B0593
CeftazidimeAntibiotic -
HY-B0330
LevofloxacinDNA Gyrase/Topoisomerase Inhibitor -
HY-17412
Minocycline hydrochlorideHIF-1α/Glutamate Inhibitor -
HY-B1455
ClindamycinLincosamide Antibiotic -
HY-B0522A
Ampicillin sodiumBacterial Inhibitor -
HY-B0692
CefepimeAntibiotic
Publications Citing Use of MedChemExpress (MCE) Ceftriaxone sodium salt
More- Signal Transduct Target Ther. 2025 Dec 15;10(1):406. [Abstract]
- Nat Commun. 2022 Mar 2;13(1):1116. [Abstract]
- Sci Adv. 2025 Dec 5;11(49):eadw7972. [Abstract]
- EBioMedicine. 2022 Apr;78:103943. [Abstract]
- Proc Natl Acad Sci U S A. 2025 Dec 2;122(48):e2524436122. [Abstract]
- Cell Chem Biol. 2024 Aug 15;31(8):1529-1541.e12. [Abstract]
- Food Res Int. 2026 Aug 31:238:119421. [Abstract]
- J Environ Chem Eng. 2026 Apr 16;14(3):122734.
- Emerg Microbes Infect. 2024 Dec;13(1):2321981. [Abstract]
- Talanta. 2026 Jul 15;312(Pt A):130306.
- BMC Microbiol. 2025 Apr 29;25(1):257. [Abstract]
- FASEB J. 2026 Jan 31;40(2):e71438. [Abstract]
- Antimicrob Agents Chemother. 2026 Apr;70(4):e0170625. [Abstract]
- Microbiol Spectr. 2025 Oct 16:e0160325. [Abstract]
- BMC Cancer. 2025 Jun 1;25(1):977. [Abstract]
- AMB Express. 2024 Dec 24;14(1):141. [Abstract]
- Infect Drug Resist. 2026 May 8;19.
- Diagn Microbiol Infect Dis. 2026 Nov;116(3):117584.
- Rapid Commun Mass Spectrom. 2026 May 30;40(10):e70053. [Abstract]
- Diagn Microbiol Infect Dis. 2026 Feb;114(2):117181. [Abstract]
- Authorea. 2026 May 12.
- Chemosphere. 2023 Dec:344:140353. [Abstract]
Customer Validation & Images
-
Microbiological Assay
-
Microbiological Assay
Alle Antibiotic Isoform-spezifische Produkte anzeigen
MoreAlle Aurora Kinase Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Beschreibung
IC50 & Target
|
β-lactam |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO | IC50 |
153.8 μM
Compound: ceftriaxone
|
Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits
Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits
|
[PMID: 23812503] |
In Vitro
Ceftriaxone sodium salt (100 μM, 24 h) protects MPP+ treated astrocytes by inhibiting the NF-κB/JNK/c-Jun signaling pathway [3].
Ceftriaxone sodium salt (500 μM, 24-48 h) effectively inhibits unanchored cell growth in A549, H520 and H1650 lung cancer cells by inhibiting Aurora B[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Astrocyte
-
Concentration:100 μM
-
Incubation Time:24 h
-
Result:Improved cell viability and increased glutamate uptake after MPP+ expose.
-
Cell Line:Astrocyte
-
Concentration:100 μM
-
Incubation Time:24 h
-
Result:Enhanced GLT-1 and GFAP expression. Decreased the expression of p-p50、p-IKKα、p-Relb. Decreased the number of TUNEL-positive cells.
In Vivo
Ceftriaxone sodium salt (200, 400 mg/kg, Intraperitoneal injection) has a protective effect on convulsion induced by Pentylenetetrazol (PTZ) and PTZ-related oxidative damage in rats[6].
Ceftriaxone sodium salt (100, 200 mg/kg, Intraperitoneal injection) reduces mechanical dysodynia and hyperalgesia by activating GLT-1 in streptozotocin (HY-13753)-induced diabetic rat models[7].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:DGL-induced rat model[5]
-
Dosage:200 mg/kg
-
Administration:i.p.
-
Result:Reduced the BUN、Cr 、AST and ALT levels. Attenuated the MDA levels and enhanced GPx and CAT activities. Reduced the levels of IL-1β and TNF-α mRNA.
-
Animal Model:PTZ-induced rat model[6]
-
Dosage:200, 400 mg/kg
-
Administration:i.p. 60 min before to PTZ (70 mg/kg)
-
Result:Both of the two ceftriaxone groups had lower spike percentages than the saline group. Significantly lower MDA levels and higher SOD activity in 200 and 400 mg/kg.
Chemical Information
-
CAS. Nr. 74578-69-1
-
Appearance Solid
-
Molecular Weight 598.54
-
Formel C18H16N8Na2O7S3
-
Color White to off-white
-
SMILES
O=C(O[Na])C(N12)=C(CSC(N(C)N=C3O[Na])=NC3=O)CS[C@]2([H])[C@H](NC(/C(C4=CSC(N)=N4)=N\OC)=O)C1=O
-
Synonyms
Ro 13-9904
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture and light)
Publications (22)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]2025 Dec 15;10(1):406. PMID: 41392286 -
Nat Commun
Antimicrobial resistance and population genomics of multidrug-resistant Escherichia coli in pig farms in mainland China. [Abstract]2022 Mar 2;13(1):1116. PMID: 35236849
Ceftriaxone sodium salt purchased from MedChemExpress. Usage Cited in: Nat Commun. 2022 Mar 2;13(1):1116. [Abstract]
E. coli strains resistant to broad-spectrum cephalosporins (ceftriaxone and cefepime) were isolated from pig farms in 30 and 24 provinces, respectively.
-
Sci Adv
EphB1-NR2B receptor signaling in glutamatergic neurons of the ventroposteromedial thalamic nucleus regulates emergence from anesthesia. [Abstract]2025 Dec 5;11(49):eadw7972. PMID: 41348875 -
EBioMedicine
A novel inhibitor of monooxygenase reversed the activity of tetracyclines against tet(X3)/tet(X4)-positive bacteria. [Abstract]2022 Apr;78:103943. PMID: 35306337 -
Proc Natl Acad Sci U S A
Antibiotics accumulate in Klebsiella pneumoniae liver abscesses but fail to eliminate antibiotic-tolerant populations. [Abstract]2025 Dec 2;122(48):e2524436122. PMID: 41296732 -
Cell Chem Biol
AspSnFR: A genetically encoded biosensor for real-time monitoring of aspartate in live cells. [Abstract]2024 Aug 15;31(8):1529-1541.e12. PMID: 38806058 -
Food Res Int
Prevalence, plasmid transmission, and chromosomal integration of blaCTX-M genes in Salmonella isolated from retail chicken and pork meats in China. [Abstract]2026 Aug 31:238:119421. PMID: 42215089 -
-
Emerg Microbes Infect
AMXT-1501 targets membrane phospholipids against Gram-positive and -negative multidrug-resistant bacteria. [Abstract]2024 Dec;13(1):2321981. PMID: 38422452 -
-
BMC Microbiol
Klebsiella pneumoniae under xylose pressure: the growth adaptation, antimicrobial susceptibility, global proteomics analysis and role of XylA and XylB proteins. [Abstract]2025 Apr 29;25(1):257. PMID: 40301709 -
FASEB J
Enhancing the Susceptibility of Methicillin-Resistant Staphylococcus aureus to β-Lactam Antibiotics Through the Use of 4-Methoxysalicyl Aldehyde. [Abstract]2026 Jan 31;40(2):e71438. PMID: 41524623 -
Antimicrob Agents Chemother
Stepwise evolution and clonal enrichment of gepotidacin resistance in Neisseria gonorrhoeae. [Abstract]2026 Apr;70(4):e0170625. PMID: 41810969 -
Microbiol Spectr
The adaptive growth and mechanisms of Klebsiella pneumoniae under sucrose and glucose exposure. [Abstract]2025 Oct 16:e0160325. PMID: 41099518 -
BMC Cancer
Cholesterol-induced colorectal cancer progression and its mitigation through gut microbiota remodeling and simvastatin treatment. [Abstract]2025 Jun 1;25(1):977. PMID: 40452015 -
AMB Express
Repurposing pinaverium bromide against Staphylococcus and its biofilms with new mechanisms. [Abstract]2024 Dec 24;14(1):141. PMID: 39718732
Ceftriaxone sodium salt purchased from MedChemExpress. Usage Cited in: AMB Express. 2024 Dec 24;14(1):141. [Abstract]
Combinational antimicrobial effects between PVB and conventional antibiotics against MRSA ATCC 43,300. TET, Tetracycline. DOX, Doxycycline. E, Erythromycin. AZI, Azithromycin. P, Penicillin. CAZ, Ceftazidime. AMP, Ampicillin. CEZ, Cefazolin. CEF, Cefotaxime. OXA, Oxacillin. CRO, Ceftriaxone. AMK, Amikacin. GEN, Gentamycin, KANA, Kanamycin. TOB, Tobramycin. SPC, Spectinomycin.
-
-
-
Rapid Commun Mass Spectrom
Sensitive Detection of Salmonella Susceptibility to Ceftriaxone and Azithromycin Using Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry. [Abstract]2026 May 30;40(10):e70053. PMID: 41704149 -
Diagn Microbiol Infect Dis
2026 Feb;114(2):117181. PMID: 41205476 -
-
Chemosphere
Sustainable production of Fe-doped MnO2 nanoparticles for accelerated tetracycline antibiotic detoxification. [Abstract]2023 Dec:344:140353. PMID: 37797898
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : 50 mg/mL (83.54 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : ≥ 40 mg/mL (66.83 mM)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture and light). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture and light). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.18 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (4.18 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 100 mg/mL (167.07 mM); Clear solution; Need ultrasonic
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Protokoll
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Gram Staining of Tissue Sections
Gram staining of tissue sections is a histochemical technique used to differentiate Gram-positive and Gram-negative bacteria within histological specimens based on differences in bacterial cell wall structure and dye retention, adapted from classical bacteriological Gram staining into tissue-compatible “histological Gram stain” variants. In tissue applications, modifications of the Brown-Hopps and Brown-Brenn methods are commonly used to improve differentiation of microorganisms embedded within host connective tissue and to reduce overstaining or loss of Gram-negative signal, which are known limitations of earlier approaches. The principle relies on crystal violet-iodine complex retention in Gram-positive organisms and subsequent decolorization and counterstaining steps that allow contrast visualization of Gram-negative organisms against tissue background.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Bacterial live/dead nucleic-acid viability staining
The LIVE/DEAD bacterial viability staining method is based on differential permeability of nucleic-acid-binding fluorescent dyes, most commonly SYTO 9 and propidium iodide (PI), which enables discrimination of bacterial populations with intact versus compromised cytoplasmic membranes. SYTO 9 penetrates both intact and damaged bacterial membranes and binds nucleic acids to produce green fluorescence, whereas propidium iodide penetrates only cells with compromised membranes and fluoresces red while also reducing SYTO 9 signal through competitive binding and fluorescence interactions. The resulting fluorescence pattern is interpreted as a proxy for membrane integrity, which is widely used as an indicator of bacterial viability in microscopy, flow cytometry, and spectroscopic platforms. However, mechanistic studies show that SYTO 9 and PI interactions involve displacement and fluorescence resonance energy transfer effects, which can influence signal interpretation depending on dye ratios a
Reinheit & Dokumentation
-
Data Sheet (284 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Nahata MC, et al. Ceftriaxone: a third-generation cephalosporin. Drug Intell Clin Pharm. 1985 Dec;19(12):900-6. [Content Brief]
[2]. Nassar H, et al. Molecular docking, molecular dynamics simulations and in vitro screening reveal cefixime and ceftriaxone as GSK3β covalent inhibitors. RSC Adv. 2023 Apr 11;13(17):11278-11290. [Content Brief]
[3]. Zhang Y, et al. Ceftriaxone Protects Astrocytes from MPP(+) via Suppression of NF-κB/JNK/c-Jun Signaling. Mol Neurobiol. 2015 Aug;52(1):78-92. [Content Brief]
[4]. Li X, et al. Ceftriaxone, an FDA-approved cephalosporin antibiotic, suppresses lung cancer growth by targeting Aurora B. Carcinogenesis. 2012 Dec;33(12):2548-57. [Content Brief]
[5]. Hakimizadeh E, et al. Ceftriaxone improves hepatorenal damages in mice subjected to D-galactose-induced aging. Life Sci. 2020 Oct 1;258:118119. [Content Brief]
[6]. Uyanikgil Y, et al. Positive effects of ceftriaxone on pentylenetetrazol-induced convulsion model in rats. Int J Neurosci. 2016;126(1):70-5. [Content Brief]
[7]. Gunduz O, et al. Anti-allodynic and anti-hyperalgesic effects of ceftriaxone in streptozocin-induced diabetic rats. Neurosci Lett. 2011 Mar 10;491(1):23-5. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture and light). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 1.6707 mL | 8.3537 mL | 16.7073 mL | 41.7683 mL |
| 5 mM | 0.3341 mL | 1.6707 mL | 3.3415 mL | 8.3537 mL | |
| 10 mM | 0.1671 mL | 0.8354 mL | 1.6707 mL | 4.1768 mL | |
| 15 mM | 0.1114 mL | 0.5569 mL | 1.1138 mL | 2.7846 mL | |
| 20 mM | 0.0835 mL | 0.4177 mL | 0.8354 mL | 2.0884 mL | |
| 25 mM | 0.0668 mL | 0.3341 mL | 0.6683 mL | 1.6707 mL | |
| 30 mM | 0.0557 mL | 0.2785 mL | 0.5569 mL | 1.3923 mL | |
| 40 mM | 0.0418 mL | 0.2088 mL | 0.4177 mL | 1.0442 mL | |
| 50 mM | 0.0334 mL | 0.1671 mL | 0.3341 mL | 0.8354 mL | |
| 60 mM | 0.0278 mL | 0.1392 mL | 0.2785 mL | 0.6961 mL | |
| DMSO | 80 mM | 0.0209 mL | 0.1044 mL | 0.2088 mL | 0.5221 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Ceftriaxone sodium salt Related Classifications
HY-B0712B Related Classifications
Powered by Bioz